By Will Feuer

Medical-technology company Haemonetics said it has received clearance from the Food and Drug Administration for enhancements to its NexSys PCS plasma-collection system.

The enhancements include a new plasma collection bowl and technology engineered to reduce procedure time, which the company expects to average between 33 minutes and 38 minutes.

The company said it is planning an initial market release of the system with its enhancements in the coming months.

The plasma business is Haemonetics' largest in terms of revenue, posting $131.2 million in the fourth quarter, up about 30% from a year ago.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

June 22, 2023 06:52 ET (10:52 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Haemonetics (NYSE:HAE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Haemonetics.
Haemonetics (NYSE:HAE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Haemonetics.